Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?
|
|
- Lucy Black
- 6 years ago
- Views:
Transcription
1 European Urology Supplements European Urology Supplements 4 (2005) Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal* Service d Urologie, Cliniques universitaire Saint-Luc UCL, Hippokrateslaan 10, 1200 Sint Lambrechts-Woluwe, Brussels, Belgium Abstract Traditionally serum testosterone castration levels were set at a minimum of 50 ng/dl. Achieving and maintaining these castration levels are the main goal of therapy with luteinising hormone releasing hormone (LHRH) agonists. As the optimal castration level remains debated, this paper aims to review published literature challenging the 50 ng/ dl definition, as well as studies evaluating the effects of LHRH agonists on testosterone suppression. A Medline search was performed in the last quarter of Only fully published studies and review articles in English language were included. The threshold of 50 ng/dl has been set arbitrarily, based on the available measuring techniques. As those techniques are developed in the late 1960s and current techniques are more accurate, this article discusses elements for defining an appropriate castration as achieving testosterone levels below 20 ng/dl. Ideally, chemical castration with LHRH agonists should achieve similar testosterone levels as those obtained with orchiectomy (15 ng/dl). As a consequence, using orchiectomy as a benchmark would favour 20 ng/dl over 50 ng/dl as a cut-off point for appropriate castration. LHRH agonists have been thought to achieve an almost 100% of response in the initial therapy. Several studies have shown that when using a more stringent definition of castration, treatment with current LHRH agonists does not achieve this goal. As a consequence, measurement of testosterone should regain attention for evaluating treatment response to LHRH agonists as well as for monitoring breakthroughs and acute-on-chronic responses. # 2005 Elsevier B.V. All rights reserved. Keywords: Prostate cancer; Testosterone; Hormonal escape; Breakthrough response; Acute-on-chronic response; LHRH agonists; Castration level; Review 1. Introduction Since the studies of Nobel Prize s laureate Charles Huggins nearly 60 years ago, it has been known that prostate cancer cells rely on a critical level of androgens to grow and survive. On this basis, androgen withdrawal, whether surgically or medically induced, has been the standard form of systemic therapy for advanced prostate cancer for more than 4 decades. For many years, oral oestrogens have been the sole alternative to surgical castration. Although relatively cheap * Tel ; Fax: address: bertrand.tombal@fymu.ucl.ac.be. and effective, they may lead to fluid retention, congestive heart failure, deep veins thrombosis, pulmonary embolism, myocardial infarction and strokes [1]. Surgical castration with bilateral orchiectomy has been regarded as the standard of castration, until Andrew Schally characterized the structure of the luteinizing hormone releasing hormone (LHRH) [2]. A. Schally investigated ways to manipulate this system, like developing synthetic peptide agonists of LHRH. Following this seminal work, several synthetic LHRH agonists were subsequently developed and tested for clinical use. Long-acting microcapsulated delivery systems for these LHRH agonists were developed that were designed to release a controlled dose of /$ see front matter # 2005 Elsevier B.V. All rights reserved. doi: /j.eursup
2 B. Tombal / European Urology Supplements 4 (2005) the peptide over 1 3 months. These agonists have been tested in several clinical trials and were found to be as effective as diethylstilbestrol (DES) in treating prostate cancer [3]. Like other approaches to lowering serum testosterone, treatment with LHRH agonists causes significant side effects, such as hot flushes, loss of libido and impotence. These agents, however, do not lead to the increased thromboembolic events that are associated with oestrogen therapy [3]. A. Schally received the Nobel Prize in Medicine in 1977 and back from these early eighties, surgical castration has been replaced by medical castration. Therapy with LHRH agonists has offered an effective and well tolerated treatment option for men diagnosed with prostate cancer, as discussed by P. Mongiat-Artus, in this supplement [4]. When opting for castration, the goal of physicians is to achieve low testosterone levels. Oefelein et al. [5] postulated the lower the better when trying to achieve castration levels of testosterone. But how low is good enough? What is an appropriate castration level? Currently, many physicians consider the achievement of testosterone levels of less than 50 ng/dl (1.73 nmol/l) as indicative for efficacy of LHRH agonist therapies. But is 50 ng/dl the appropriate cut-off point? This article will discuss in more detail the issues related to the achievement of testosterone castration levels of 50 ng/dl and will evaluate 20 ng/dl (0.7 nmol/l) as a more appropriate cut-off point. 2. Castration levels Serum testosterone is considered to be suppressed if two consecutive (on separate days) values of less than 50 ng/dl occurred. Onset of suppression is considered to be the first day on which these suppressed values occurred [6]. This definition, postulated by Sharifi et al. [6], was applied in many clinical trials. Most physicians consider LHRH agonists efficacious when achieving testosterone levels below 50 ng/dl. The importance of low testosterone levels has been recognised for a long time. In 1977, studies with 0.2 mg DES demonstrated that ineffective androgen suppression therapy results in higher prostate cancer mortality [1,7]. Today appropriate testosterone reduction is still the main goal to treat locally advanced and metastatic prostate cancer. Amazingly, only few authors have challenged the historically set definition of 50 ng/dl, since the availability of newer and more accurate dosing methods Old assay methods The testosterone castrate levels of 50 ng/dl are derived from old assay methods. The double-isotopederivate dilution technique to measure serum testosterone was developed in the late 1960s and early 1970s [8]. However, this technique has been reported to have limitations in accuracy and is no longer used [9]. In 1995, the fully automated immunoassay analyser, using chemiluminescent technology, was approved for clinical use. This technique already permitted more accurate serum testosterone measurements, while also decreasing the waiting time for results [10]. Currently, the sensitivity of the assays used to measure serum testosterone levels are as low as 0.1 ng/ml [11]. Development of these new analytical methods, like chemiluminescent testing, makes it possible to detect serum testosterone levels more accurately and well below 50 ng/dl Orchiectomy as benchmark Oefelein et al. [8] undertook a study to re-evaluate the castrate level achieved with orchiectomy using modern dosing methods (chemiluminescent immunoassay method). A group of 35 patients with advanced prostate cancer underwent bilateral orchiectomy and received no additional hormonal therapies. Thirtythree months after orchiectomy, median total testosterone was decreased to 15 ng/dl (0.5 nmol/l; 95% CI 12 to 17 ng/dl). Additionally, the maximum and minimum testosterone values observed were 30 and less than 10 ng/dl, respectively. Overall, the most important observation of this study is that patients after orchiectomy rarely exceed the testosterone threshold of 20 ng/dl. Consequently, one could postulate that 20 ng/dl is a more appropriate cut-off point for defining castration. When reviewing other studies investigating the safety and efficacy of orchiectomy in prostate cancer patients, similar results were found. Kaisary et al. [12] found that mean serum testosterone decreased by week 4 after orchiectomy to 0.91 nmol/l (26.3 ng/dl) in patients with metastatic disease. Røhl and Beuke [13] reported even lower values. One month after orchiectomy, median serum testosterone decreased towards nmol/l (21.0 ng/dl). Lin et al. [14] compared the time to castration between oral oestrogen and bilateral orchiectomy in 20 patients with metastatic disease. The threshold of castrate serum testosterone was considered to be less than 20 ng/dl. Between 3 and 12 hours (mean hours) after patients underwent orchiectomy, all men managed to achieve this low testosterone level. Vogelzang et al. [15] com-
3 16 B. Tombal / European Urology Supplements 4 (2005) pared medical castration with goserelin versus orchiectomy in 283 patients with stage D2 prostate cancer. Also in this study, patients who underwent orchiectomy reached castrate levels of 20.0 ng/dl at week 4. If we take a testosterone level below 20 ng/dl as the definition of optimal castration, the question arises whether LHRH agonists administration achieves this goal in the majority of patients. Oefelein et al. [16] addressed this question and enrolled 38 patients with prostate cancer to investigate the failure of achieving this castration level after LHRH agonist therapy. All 38 patients in this study received a 3-month depot LHRH agonist (leuprolide or goserelin) and 750 mg flutamide daily. In a significant number of patients (13%) on androgen suppression therapy, the 20 ng/dl castrate cut-off was not achieved and in about 5% of patients, values below 50 ng/dl were not achieved. These results have been confirmed by several other groups (Fig. 1) Trends towards 20 ng/dl castration levels Most physicians use the testosterone castration threshold of 50 ng/dl in daily clinical practice. Also many studies evaluating the efficacy and safety of several LHRH agonists use this cut-off point for reporting results. With the advent of the modern dosing methods, more recent studies [17 20] recognise the importance of accurately measuring testosterone levels and also report the number of patients below 20 ng/dl testosterone. In some publications, like the 2002 study of Kawakami et al. [20], only reports on efficacy using a 20 ng/dl cut-off are used. This study demonstrated that 17.6% of patients did not reach this castrate level. Fig. 1. The percentage of patients that do not reach testosterone castration levels below 50 ng/dl is negligible. Setting the castration threshold on 20 ng/dl is more reliable, as seen that more patients do not reach this threshold [16 18,29]. 1, 3 M: depot formulation of respectively 1 or 3 months; L: leuprolide. 3. Hormonal escapes Although most patients reach testosterone castration levels after 3 4 weeks, there is always the possibility of a hormonal escape during LHRH agonist therapy. A hormonal escape, which is defined as an increase in serum testosterone after castration levels have been achieved, is an important clinical consideration. Although these testosterone escapes are indications for a therapeutic failure, they are often not recognised by the physician. Also, no clear definition exists regarding hormonal escapes. One can divide hormonal escapes into breakthrough responses and acute-onchronic responses. In order to discriminate between patients having a breakthrough response and patients suffering from an acute-on-chronic response, both will be discussed in more detail below. In its conventional definition serum testosterone is considered suppressed appropriately if its levels decline below 50 ng/dl [6]. As a consequence, both breakthrough and acute-on-chronic responses occur after the patient has reached castrate levels below 50 ng/dl. A breakthrough response is defined as the occurrence of one single testosterone increase above 50 ng/dl, during the whole LHRH agonist treatment period. An acute-on-chronic response, on the other hand, is associated with the administration of the LHRH agonist. In contrast with the flare phenomenon, an acute-on-chronic response is not associated with the first LHRH agonist injection, but only from the second and subsequent injections. Also, this escape needs to be detected at maximally 12 hours following re-injection to be defined as an acute-on-chronic response [6,17] Breakthrough response As seen in Fig. 2, about 7% of patients will experience a breakthrough response during their treatment period with a LHRH agonist. Sarosdy et al. [21] reports a study of 58 patients with advanced or metastatic prostate cancer who received 10.8 mg goserelin every 13 weeks. Only one patient (2%) reported a breakthrough response, at week 8. Unfortunately, the authors did not mention if the response was associated with increased side effects. Long-term follow-up results of Jocham et al. [22] reported the efficacy of a 3-month leuprolide (11.25 mg) depot in 62 patients with advanced prostate cancer. Four patients (6.5%) were identified with a breakthrough response. Two of them had only one increase above 50 ng/dl, but one patient had fluctuating testosterone levels throughout the follow-up. One patient reported increased testosterone levels, accom-
4 B. Tombal / European Urology Supplements 4 (2005) Fig. 2. About 7% of patients receiving LHRH agonists will have a breakthrough response, if the castration level is set at 50 ng/dl [21 23]. 3 M: 3 month depot formulation; G: goserelin; L: leuprolide. panied by local tumour response, this breakthrough response is clearly an indication for a therapeutic failure. Khan et al. [23] also investigated the efficacy of a 3- month depot of leuprolide (11.25 mg) in patients with advanced prostate cancer (n = 24). Before the re-injection, 3 patients (12.5%) reported a breakthrough response defined as a testosterone increase above 50 ng/dl Acute-on-chronic response Fig. 3 shows the percentage of patients with an acute-on-chronic response after re-injection with a LHRH agonist for two different thresholds. A study comparing the 1- and 3-month depot formulations of leuprolide (7.5 mg and 22.5 mg, respectively) enrolled 71 patients with advanced prostate cancer [6]. In the 1-month depot group, 2 patients Fig. 3. If the castration level is set at 50 ng/dl, about 6% of patients will have an acute-on-chronic response [6,21,24]. 1, 3 M: depot formulation of respectively 1 or 3 months; G: goserelin; L: leuprolide. (5.9%) had minor testosterone increases following the second depot injection. One patient had increases towards 53 ng/dl (4 hours after re-injection) and the second patient towards 56 ng/dl (8 hours after re-injection). One patient (2.9%) experienced a testosterone increase after the third depot injection. In the 3- month depot group, no values greater than 50 ng/dl were seen after re-stimulation. Sarosdy et al. [21] reported on the efficacy of the 3-month depot formulation (10.8 mg) of goserelin. Six patients (10%) showed rising testosterone levels of respectively 56, 58, 60, 75, 111 and 192 ng/dl. Zinner et al. [24] compared the 1-month (3.6 mg) and the 3-month (10.8 mg) depot injections of goserelin in 237 patients with advanced prostate cancer. Acute-on-chronic responses occurred in 34 patients (27.0%) of the 1-month goserelin group and in 20 patients (17.7%) of the 3-month goserelin group. The magnitude of the testosterone surge to greater than 18.5 ng/dl ranged from ng/dl in the 1-month goserelin group, and ng/dl in the 3-month goserelin group. However, the testosterone castration range was set at 18.5 ng/dl, which explains the higher number of patients with an acute-on-chronic response as compared to previous studies. 4. Testosterone as a trigger for re-dosing depot LHRH agonists Oefelein et al. [16] found that 5% of patients failed to achieve the castrate level of 50 ng/dl and 13% of patients fail to achieve castrate levels of 20 ng/dl. These findings support the conclusion that the standard dose of depot LHRH agonists may be inadequate in some men. However, it has also been reported that depot LHRH agonists provide an excessive castrate testosterone duration [25]. Consequently, re-dosing of depot LHRH agonists based on serum testosterone has been proposed [26]. Thirty-two men diagnosed with prostate cancer stage T3N or more, received the LHRH agonist leuprolide in a 3-month depot injection. Castration levels were defined as 20 ng/dl or less. The median duration of castration was 6.0 months (range ). As seen in Fig. 4, median serum testosterone values beginning 3 months after the last leuprolide depot injection, and monthly intervals thereafter, remain below the castrate level of 20 ng/dl for up to 7 months. Maximum testosterone values only exceed the 50 ng/dl threshold after 7 months, demonstrating the long acting effect of a 3 month depot leuprolide injection. Recently, health related quality of life (QoL) has been assessed in patients with prostate cancer on
5 18 B. Tombal / European Urology Supplements 4 (2005) These data have significant implications. The design and interpretation of clinical trials of LHRH agonists in a neoadjuvant or adjuvant treatment must consider the time-course of testosterone recovery. An option here is that testosterone levels should be measured during the study as well as prostate specific antigen (PSA) levels. 5. Conclusion Fig. 4. Median serum testosterone level remains below 20 ng/dl for up to 6 months, after the administration of a 3-month depot LHRH agonist [26]. LHRH agonist therapy, who were re-dosed based on serum testosterone values [27]. Patients received a 3-month depot LHRH agonist (goserelin) to achieve testosterone castration levels below 20 ng/dl. If testosterone increased above this threshold, goserelin was re-administered and a new cycle was repeated. The median duration of castrate testosterone levels was 5.5 months (mean 6 months, range ). However, the most important observation was that the patient s assessed health related QoL was improved in the short term and the cost of care was decreased by 50% with no loss in the patient s satisfaction. Hall et al. [28] also reported these prolonged results after cessation of therapy. Patients in this study group had received LHRH agonist therapy for 24 months or longer, until therapy was stopped. Twelve months after cessation, 28.6% of patients still had castrate levels below 50 ng/dl. Median testosterone level for all patients remained in the castrate range at 6 months (44.0 ng/dl) and at 9 months (44.5 ng/dl). The importance of effective androgen suppression therapy is well recognised because ineffective testosterone suppression may result in increased prostate cancer mortality. The availability of new and more accurate assay methods has enabled to detect serum testosterone levels below the threshold of 20 ng/dl. This has triggered the question whether achieving testosterone levels below 50 ng/dl corresponds to optimal castration. If one uses the castration level obtained with orchiectomy as benchmark, 20 ng/dl is a better cutoff point for defining appropriate castration and treatment response. Recent publications have shown that several patients treated with current LHRH agonist formulations do not achieve appropriate castration levels, show breakthroughs and acute-on-chronic responses, particularly if one uses the more stringent definition of 20 ng/dl. Physicians today are not routinely evaluating the testosterone level when initiating and evaluating therapy. The measurement of testosterone should become part of clinical practice when evaluating the effects of hormonal therapy. References [1] Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7: [2] Schally AV, Kastin AJ, Arimura A. Hypothalamic FSH and LHregulating hormone. Structure, physiology and clinical studies. Fertil Steril 1971;22: [3] The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311: [4] Mongiat-Artus P, Teillac P. Role of luteinising hormone releasing hormone (LHRH) agonists in the management of prostate cancer. Eur Urol Suppl 2005;4(5):4 13. [5] Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003;62(2): [6] Sharifi R, Browneller R, Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002;168(3): [7] Jordan WP, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977; 70: [8] Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): [9] Wilke TJ, Utley DJ. Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem 1987;33(8): [10] Wheeler MJ, D Souza A, Matadeen J, Croos P. Ciba Corning ACS:180 testosterone assay evaluated. Clin Chem 1996;42(9): [11] Zherdev AV, Byzova NA, Izumrudov VA, Dzantiev BB. Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples. Analyst 2003;128(10): [12] Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5): [13] Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992;26(1):11 4.
6 B. Tombal / European Urology Supplements 4 (2005) [14] Lin BJ, Chen KK, Chen MT, Chang LS. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 1994;43(6): [15] Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith Jr JA, et al., Zoladex Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995;46(2): [16] Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164(3 Pt 1): [17] Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24(11): [18] Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3): [19] Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA mg: a new 4- month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003;62(2): [20] Kawakami J, Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen supression with LHRH agonists. J Urol 2002;167(Suppl. 4):288 (abs. 1135). [21] Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, et al. Endocrine effects, efficacy and tolerability of a mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83(7): [22] Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 1998;60(Suppl 2): [23] Khan MS, O Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998; 60(1): [24] Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004; 64(6): [25] Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160(5): [26] Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999;54(4): [27] Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 2003;169(1): [28] Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999;53(5): [29] McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, et al., Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):
Expert Opinion on Optimal Testosterone Control in Prostate Cancer
European Urology Supplements European Urology Supplements 4 (2005) 37 41 Expert Opinion on Optimal Testosterone Control in Prostate Cancer Alex Zlotta a,1, Frans M.J. Debruyne b, * a Department of Urology,
More informationWhat is New in Hormone Therapy for Prostate Cancer in 2007?
european urology supplements 7 (2008) 477 483 available at www.sciencedirect.com journal homepage: www.europeanurology.com What is New in Hormone Therapy for Prostate Cancer in 2007? Bertrand Tombal *
More informationEffect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer
Current Medical Research and Opinion Vol. 22, No. 4, 2006, 649 655 2006 LibraPharm Limited 0300-7995 doi:10.1185/030079906x96425 All rights reserved: reproduction in whole or part not permitted 211333
More informationHormone Therapy: Improving Therapy Decisions and Monitoring
european urology supplements 5 (2006) 369 376 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy: Improving Therapy Decisions and Monitoring Alexandre R. Zlotta
More informationEligard W 6: A New Form of Treatment for Prostate Cancer
european urology supplements 5 (2006) 905 910 available at www.sciencedirect.com journal homepage: www.europeanurology.com Eligard W 6: A New Form of Treatment for Prostate Cancer Oliver Sartor * Dana
More informationGoserelin versus leuprolide in the chemical castration of patients with prostate cancer
Int Urol Nephrol (2012) 44:1039 1044 DOI 10.1007/s11255-012-0134-z UROLOGY ORIGINAL PAPER Goserelin versus leuprolide in the chemical castration of patients with prostate cancer Élcio Dias Silva Ubirajara
More informationClinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists
original research research research Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists Jun Kawakami, MD, FRCSC; * Alvaro Morales, MD, FRCSC, OC *Department
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationProstate cancer is now the most
: a new hormonal treatment for prostate cancer Professor Malcolm Mason, School of Medicine, Cardiff University, Velindre Hospital, Whitchurch, Cardiff - hypothalamus According to NICE, prostate cancer
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationManipulating Hormones: Androgen Suppression in Prostate Cancer Patients
Focus on CME at the University of Queen s ManitobaUniversity Manipulating Hormones: Androgen Suppression in ostate Cancer Patients By D. Robert Siemens, MD, FRCSC Case A 62-year old man presents with complaints
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationlower testosterone levels with LHRH agonist therapy than with surgical castration: new insights attained by mass spectrometry
6 lower testosterone levels with LHRH agonist therapy than with surgical castration: new insights attained by mass spectrometry Hong N. Bui, Tim M. van der Sluis, Eric J.H. Meuleman, Annemieke C. Heijboer,
More informationMaximal androgen blockade versus castration alone in patients with metastatic prostate cancer*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0037-9 September 2014, Vol. 13, No. 9, P417 P421 Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer* Abeer
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationHormonotherapy of advanced prostate cancer
Annals of Oncology 16 (Supplement 4): iv80 iv84, 2005 doi:10.1093/annonc/mdi913 Hormonotherapy of advanced prostate cancer P. Pronzato & M. Rondini Department of Oncology, Felettino Hospital, La Spezia,
More informationImproving Flexibility and Quality of Life for Your Patients: A Must?
EUROPEAN UROLOGY SUPPLEMENTS 8 (2009) 857 862 available at www.sciencedirect.com journal homepage: www.europeanurology.com Improving Flexibility and Quality of Life for Your Patients: A Must? Axel Heidenreich
More informationAndrogen deprivation therapy: New concepts. Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto
Androgen deprivation therapy: New concepts Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto Clinical Research funding: 1. Bayer/Algeta 2. Ferring 3. Abbott 4. GSK 5. EMD Serono
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationHormoneTherapy in Prostate Cancer: LHRH Antagonists
European Urology European Urology 46 (2004) 279 284 Review HormoneTherapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues Dorothea Weckermann *, Rolf Harzmann Department of Urology, Klinikum
More informationUnrecognized Kinetics of Serum Testosterone: Impact on Short- Term Androgen Deprivation Therapy for Prostate Cancer
Original Article http://dx.doi.org/10.3349/ymj.2014.55.3.570 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(3):570-575, 2014 Unrecognized Kinetics of Serum Testosterone: Impact on Short- Term Androgen
More informationMiyazawa et al. Basic and Clinical Andrology (2015) 25:7 DOI /s
Miyazawa et al. Basic and Clinical Andrology (2015) 25:7 DOI 10.1186/s12610-015-0023-2 RESEARCH ARTICLE Open Access Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in
More informationTreatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients
Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients ROBERT L. LEIBOWITZ, STEVEN J. TUCKER Compassionate Oncology Medical Group,
More informationDegarelix (Firmagon) induction and maintenance for advanced hormone-dependent prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Degarelix (Firmagon) induction and maintenance for advanced hormone-dependent prostate cancer Degarelix (Firmagon) induction and maintenance for advanced hormone-dependent
More informationRole of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer
European Urology Supplements European Urology Supplements 4 (2005) 4 13 Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationGuidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer
Peterborough City Hospital Department of Urology Guidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer Hormonal Therapy - How does it work? Prostate Cancer relies on the presence
More informationPACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)
ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8
More informationSix-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy and Tolerability
Original article 2015 Journal of Medical Drug Reviews. All rights reserved. J Med Drug Rev 2015;5:33 38 Six-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy
More informationEfficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer
Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer Jean De La Rosette, Ronald Davis Iii, David Frankel, Tine
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMarketing Authorisation Holder Applicant Invented name. Route of administration. Content (concentration) Member State. l form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT AND MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 1 Member State Marketing Authorisation
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationCarcinoma of the prostate gland is now recognized
Original Article 577 Tolerability Assessment of Maximal Androgen Blockade with 50 mg Daily of Bicalutamide and Castration in Patients with Advanced Prostate Cancer Cheng-Keng Chuang, MD, PhD; Sheng-Hsien
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationLuteinising hormone-releasing hormone (LHRH) agonists in prostate cancer
B88 April 2015 2.1 Community Interest Company Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer This bulletin focuses on luteinising hormone-releasing hormone (LHRH) agonists. Currently
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationReport on New Patented Drugs Trelstar LA
Report on New Patented Drugs Trelstar LA Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationeuropean urology 50 (2006)
european urology 50 (2006) 483 489 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Duration of Testosterone Suppression after a 9.45 mg Implant of the GnRH-Analogue
More informationCost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy
available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy S. Iannazzo, EngD,
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationCorrelation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations
552468JMHXXX10.1177/1557988314552468American Journal of Men s HealthReis et al. research-article2014 Article Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated
More informationFIRMAGON/DEGARELIX. Compiled by Charles (Chuck) Maack Prostate Cancer Activist/Mentor
FIRMAGON/DEGARELIX The Advantage of this GnRH/LHRH antagonist over that of GnRH/LHRH agonists particularly when administered to patients with known prostate cancer metastases Compiled by Charles (Chuck)
More informationOncologist. The. Fundamentals of Cancer Medicine. Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment
The Oncologist Fundamentals of Cancer Medicine Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment TERRY COOK, WILLIAM P. SHERIDAN Amgen Inc., Thousand Oaks, California, USA
More informationmajority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship
More informationTHINGS ARE NOT ALWAYS AS THEY APPEAR. Assume Nothing!
THINGS ARE NOT ALWAYS AS THEY APPEAR Assume Nothing! UP SIDE DOWN WORLD OF PROSTATE CANCER Paul D. Thompson, M.D. Fort Worth Texas WHAT WE THOUGHT WE KNEW AND WHAT WE KNOW TODAY FINANCIAL DISCLOSURES
More informationThe Importance of Prognostic Factors in Advanced Prostate Cancer
The Importance of Prognostic Factors in Advanced Prostate Cancer MarkS. Soloway, MD Three factors were identified in a multivariate analysis of prognostic factors in men with metastatic prostate cancer
More informationRisks and Benefits of Hormonal Manipulation as Monotherapy or AdjuvantTreatment in Localised Prostate Cancer
European Urology European Urology 48 (2005) 900 905 Risks and Benefits of Hormonal Manipulation as Monotherapy or AdjuvantTreatment in Localised Prostate Cancer P.-A. Abrahamsson a, *, J. Anderson b, L.
More informationPCa Commentary. Volume 79 May June 2014
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 79 May June 2014 CONTENT: Active Surveillance Page 1 Firmagon and Lupron Page 5 ACTIVE SURVEILLANCE:
More informationAndrogen Deprivation Therapy Its impact and the nursing role. Jane Thacker Uro-Oncology Nurse Specialist
Androgen Deprivation Therapy Its impact and the nursing role Jane Thacker Uro-Oncology Nurse Specialist Overview of content To gain an understanding of ADT (androgendeprivation therapy) and why and how
More informationFinal Appraisal Report. Ferring Pharmaceuticals Ltd. Advice No: 2109 December Recommendation of AWMSG
Final Appraisal Report Degarelix (Firmagon ) for the treatment of advanced hormone-dependent prostate cancer Ferring Pharmaceuticals Ltd Advice No: 2109 December 2009 Recommendation of AWMSG Degarelix
More informationIntroduction. Key Words: androgen deprivation therapy, prostate cancer, castration resistant prostate cancer, androgen receptor, CRPC
Traditional androgen ablation approaches to advanced prostate cancer: new insights Kyle O. Rove, MD, E. David Crawford, MD Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora,
More informationThe New England Journal of Medicine BILATERAL ORCHIECTOMY WITH OR WITHOUT FLUTAMIDE FOR METASTATIC PROSTATE CANCER
BILATERAL ORCHIECTOMY WITH OR WITHOUT FLUTAMIDE FOR METASTATIC PROSTATE CANCER MARIO A. EISENBERGER, M.D., BRENT A. BLUMENSTEIN, PH.D., E. DAVID CRAWFORD, M.D., GARY MILLER, M.D., PH.D., DAVID G. MCLEOD,
More informationFrancesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
More informationNEW ZEALAND DATA SHEET
1 NEW ZEALAND DATA SHEET NAME OF MEDICINE ZOLADEX 10.8 mg Goserelin (present as goserelin acetate) 10.8 mg injection. PRESENTATION A sterile, white to cream coloured cylindrical depot in which goserelin
More informationThe Current State of Hormonal Therapy for Prostate Cancer
The Current State of Hormonal Therapy for Prostate Cancer The Current State of Hormonal Therapy for Prostate Cancer Beth A. Hellerstedt, MD; Kenneth J. Pienta, MD Dr. Hellerstedt is Fellow, Division of
More informationThis leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved June 2013.
This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved June 2013. 1. NAME OF THE MEDICINAL PRODUCT ZOLADEX TM 2. QUALITATIVE AND QUANTITATIVE
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationMechanism: How ADT accelerates CVD?
Mechanism: How ADT accelerates CVD? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials and conflict of interests Professor
More informationAndrogen Deprivation Therapy A Question of Timing
Androgen Deprivation Therapy A Question of Timing James Johnston BSc MBChB FRACS (Urol) Disclosure 1 OUTLINE History Watchful waiting Node positive patient Recurrence Intermittent Androgen Suppression
More informationand Sayo Suda Takeshi Kashiwabara *
Kashiwabara and Suda BMC Cancer (2018) 18:619 https://doi.org/10.1186/s12885-018-4541-0 RESEARCH ARTICLE Open Access Usefulness of combined androgen blockade therapy with gonadotropinreleasing hormone
More informationBJUI. Study Type Therapy (RCT) Level of Evidence 1b OBJECTIVE CONCLUSION
. JOURNAL COMPILATION 9 BJU INTERNATIONAL Urological Oncology SCHRÖDER ET AL. BJUI BJU INTERNATIONAL Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide:
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationEVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Abraham Morgentaler, MD Director and Founder Men s Health Boston Associate Clinical Professor Harvard Medical School And the Urology
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE For Leuprorelin (Prostap 3 DCS ) for advanced hormone dependent prostate cancer Implementation Date: Review Date: This guidance has been prepared and approved for use within Gateshead,
More informationADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT?
ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT? Igor Tsaur University Medicine Mainz COI Urologische Klinik und Poliklinik Off-label use of drugs, devices, or other agents:
More informationClinical Practice Considerations for Androgen Deprivation Therapy
Published as a Promotional Supplement to September 2016 Clinical Practice Considerations for Androgen Deprivation Therapy Expert Panel Discussion Sponsored by Clinical Practice Considerations for Androgen
More informationSystematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials
Urological Oncology EARLY VS DEFERRED HORMONAL TREATMENT OF LAPC BOUSTEAD and EDWARDS Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized
More informationAssessing the attitudes to prostate cancer treatment among European male patients
Supp Article ATTITUDES TO PROSTATE CANCER TREATMENT AMONG EUROPEAN MEN SCHULMAN Assessing the attitudes to prostate cancer treatment among European male patients Claude Schulman Department of Urology,
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationDelaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures
Eur Urol 2001;40(suppl 2):17 23 Delaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures M. Wirth Department of Urology, Technical University of Dresden, Germany Key
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More informationJanuary Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic
More informationIntermittent Androgen Suppression - A standard of care or a good second choice?
Intermittent Androgen Suppression - A standard of care or a good second choice? Dr Nicholas Buchan Uro-oncology Fellow Olympic Medal Standings Gold Silver Bronze USA 9 15 13 Germany 10 13 7 Canada 14 7
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationPaul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia 5-year prostate cancer specific survival rates have improved from 67% to 99% between 1974 and 2000 Excellent survival
More informationNEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING
NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya
More informationReport on New Patented Drugs Trelstar
Report on New Patented Drugs Trelstar Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
More informationSUPPLEMENTARY APPENDIX. COU-AA-301 enrolled men with pathologically confirmed mcrpc who had received previous
SUPPLEMENTARY APPENDIX Methods Subjects COUAA30 enrolled men with pathologically confirmed mcrpc who had received previous treatment with docetaxel chemotherapy and had documented PSA progression according
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More information